Agenus Makes Senior Regulatory and Clinical Appointments
12 September 2022 - 02:30PM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of therapeutics designed to activate the immune response
to cancers and infections, today announced the appointment of
Patricia Carlos as Chief Regulatory, Quality, and Safety Officer;
Todd Yancey, MD as Global Clinical Development, Medical Affairs and
Commercial Development Advisor.
“Our upcoming worldwide Phase 2 botensilimab “ACTIVATE” programs
in MSS colorectal cancer and metastatic melanoma are advancing two
important indications based on the robust early clinical activity
achieved to date across nine treatment-resistant tumor types,” said
Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus.
“Patricia and Todd bring extensive experience across all stages of
clinical development and commercialization and will be integral to
advancing our deep pipeline of checkpoint inhibitors, immune
activators, and tumor microenvironment conditioning agents,
including botensilimab.”
Patricia Carlos has more than 20 years of
regulatory affairs leadership experience, directing programs from
investigational new drug application to commercialization. Prior to
joining Agenus, Patty served as Senior Vice President of Regulatory
and Quality at Arcus Biosciences, where she built out the
Regulatory, Quality and Safety functions and led the global
regulatory strategy. Prior to Arcus, Patty has held leadership
roles at BeiGene, Medivation, Gilead Sciences, and Bayer.
“I am thrilled to join Agenus at a critical point in the
acceleration of the botensilimab development programs. The data
generated in the early clinical trials of botensilimab study
underscore its potential to provide tremendous benefit to patients
with cold tumors that do not respond to approved therapies,” said
Carlos.
Todd Yancey, MD, has 40 years of combined
clinical and industry experience. For the last 20 years, he has
held global leadership roles of increasing responsibility in
Medical Affairs, Clinical Development, and Product
Commercialization. Prior to joining Agenus, Dr. Yancey served as
Senior Vice President, Global Medical Affairs and New Market
Development at BeiGene, Inc. Prior to his work at BeiGene, Dr.
Yancey held senior positions at BioMarin, Medivation, Onyx,
Genentech and Amgen.
“After forty years in medicine, it is a tremendous privilege to
work with the global and patient-focused team at Agenus supporting
the effort to bring forth potentially practice-changing,
next-generation immuno-oncology therapeutics for patients,” said
Dr. Yancey.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer and infections. The Company's vision
is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a
broad repertoire of antibody therapeutics, adoptive cell therapies
(through its subsidiary MiNK Therapeutics), and adjuvants (through
its subsidiary SaponiQx). The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to our technologies,
therapeutic candidates, and capabilities, for instance, statements
regarding therapeutic benefit and efficacy, mechanism of action,
potency, durability, and safety and tolerability profile of our
therapeutic candidates, both alone and in combination with each
other and/or other agents; statements regarding future plans,
including research, clinical, regulatory, and commercialization
plans; and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"will" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission and
available on our website: www.agenusbio.com. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
ContactEthan LovellChief External Affairs &
Communications Officer339-927-1763ethan.lovell@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024